Mariana Oncology is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted peptide-based radiopharmaceuticals. The company's radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets to deliver alpha or beta-emitting radionuclide payloads. By engineering molecules designed to penetrate solid tumors better than antibodies and deliver optimized high radiation activity doses without the side effects associated with chemotherapy and toxin-based strategies, Mariana Oncology aims to transform the treatment of cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/07/23 | $175,000,000 | Series B |
Access Biotechnology Atlas Venture Deep Track Capital  Eli Lilly and Company Forbion Capital Partners Nextech Invest RA Capital Management Surveyor Capital | undisclosed |
